Zai Lab (ZLAB) Competitors

Summit Therapeutics (NASDAQ:SMMT) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends.

Which has more risk & volatility, SMMT or ZLAB?

Summit Therapeutics has a beta of -1.06, indicating that its share price is 206% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.

Is SMMT or ZLAB more profitable?

Summit Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -60.26%. Zai Lab's return on equity of -33.35% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-62.87%	-51.61%
Zai Lab	-60.26%	-33.35%	-23.28%

Do institutionals & insiders believe in SMMT or ZLAB?

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 84.9% of Summit Therapeutics shares are held by company insiders. Comparatively, 5.0% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has better valuation and earnings, SMMT or ZLAB?

Summit Therapeutics has higher earnings, but lower revenue than Zai Lab. Summit Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	$700K	21,813.28	-$221.32M	-$0.34	-60.47
Zai Lab	$398.99M	9.55	-$257.10M	-$2.49	-13.88

Does the MarketBeat Community prefer SMMT or ZLAB?

Summit Therapeutics received 83 more outperform votes than Zai Lab when rated by MarketBeat users. However, 64.53% of users gave Zai Lab an outperform vote while only 58.26% of users gave Summit Therapeutics an outperform vote.

Company	Underperform	Outperform
Summit Therapeutics	Outperform Votes 314 58.26%	Underperform Votes 225 41.74%
Zai Lab	Outperform Votes 231 64.53%	Underperform Votes 127 35.47%

Do analysts prefer SMMT or ZLAB?

Summit Therapeutics currently has a consensus target price of $35.09, suggesting a potential upside of 70.68%. Zai Lab has a consensus target price of $47.37, suggesting a potential upside of 37.10%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Summit Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Zai Lab	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the media prefer SMMT or ZLAB?

In the previous week, Summit Therapeutics had 7 more articles in the media than Zai Lab. MarketBeat recorded 12 mentions for Summit Therapeutics and 5 mentions for Zai Lab. Zai Lab's average media sentiment score of 1.04 beat Summit Therapeutics' score of 0.85 indicating that Zai Lab is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Summit Therapeutics beats Zai Lab on 11 of the 19 factors compared between the two stocks.